

Ju-Tao Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/160321/publications.pdf>

Version: 2024-02-01

89
papers

7,192
citations

44069

48
h-index

56724

83
g-index

92
all docs

92
docs citations

92
times ranked

6810
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Alpha Interferon on the Hepatitis C Virus Replicon. <i>Journal of Virology</i> , 2001, 75, 8516-8523.	3.4	437
2	Identification of Five Interferon-Induced Cellular Proteins That Inhibit West Nile Virus and Dengue Virus Infections. <i>Journal of Virology</i> , 2010, 84, 8332-8341.	3.4	292
3	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	7.3	269
4	Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA Formation. <i>Journal of Virology</i> , 2007, 81, 12472-12484.	3.4	267
5	Interferon-Induced Cell Membrane Proteins, IFITM3 and Tetherin, Inhibit Vesicular Stomatitis Virus Infection via Distinct Mechanisms. <i>Journal of Virology</i> , 2010, 84, 12646-12657.	3.4	263
6	Identification of Three Interferon-Inducible Cellular Enzymes That Inhibit the Replication of Hepatitis C Virus. <i>Journal of Virology</i> , 2008, 82, 1665-1678.	3.4	255
7	Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. <i>PLoS Pathogens</i> , 2013, 9, e1003494.	4.7	204
8	Replication of Hepatitis C Virus Subgenomes in Nonhepatic Epithelial and Mouse Hepatoma Cells. <i>Journal of Virology</i> , 2003, 77, 9204-9210.	3.4	199
9	Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4277-4288.	3.2	194
10	Apoptosis and Regeneration of Hepatocytes during Recovery from Transient Hepadnavirus Infections. <i>Journal of Virology</i> , 2000, 74, 1495-1505.	3.4	168
11	Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6756-6761.	7.1	161
12	Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids. <i>Journal of Virology</i> , 2013, 87, 6931-6942.	3.4	154
13	DNA Polymerase δ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. <i>PLoS Pathogens</i> , 2016, 12, e1005893.	4.7	152
14	Molecular Virology of Hepatitis B Virus for Clinicians. <i>Clinics in Liver Disease</i> , 2007, 11, 685-706.	2.1	151
15	Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2. <i>Journal of Virology</i> , 2020, 94, .	3.4	139
16	Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes. <i>PLoS Pathogens</i> , 2013, 9, e1003613.	4.7	135
17	IFITM Genes, Variants, and Their Roles in the Control and Pathogenesis of Viral Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 3228.	3.5	129
18	Regulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction Pathway. <i>Journal of Virology</i> , 2007, 81, 10072-10080.	3.4	124

#	ARTICLE	IF	CITATIONS
19	Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. <i>Antiviral Research</i> , 2015, 122, 91-100.	4.1	122
20	Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus. <i>Journal of Virology</i> , 2010, 84, 9332-9340.	3.4	114
21	Production and Function of the Cytoplasmic Deproteinized Relaxed Circular DNA of Hepadnaviruses. <i>Journal of Virology</i> , 2010, 84, 387-396.	3.4	113
22	Chronic hepatitis B: What should be the goal for new therapies?. <i>Antiviral Research</i> , 2013, 98, 27-34.	4.1	112
23	Activation of Pattern Recognition Receptor-Mediated Innate Immunity Inhibits the Replication of Hepatitis B Virus in Human Hepatocyte-Derived Cells. <i>Journal of Virology</i> , 2009, 83, 847-858.	3.4	108
24	A Southern Blot Assay for Detection of Hepatitis B Virus Covalently Closed Circular DNA from Cell Cultures. <i>Methods in Molecular Biology</i> , 2013, 1030, 151-161.	0.9	107
25	Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. <i>PLoS Pathogens</i> , 2017, 13, e1006296.	4.7	107
26	Indoleamine 2,3-Dioxygenase Mediates the Antiviral Effect of Gamma Interferon against Hepatitis B Virus in Human Hepatocyte-Derived Cells. <i>Journal of Virology</i> , 2011, 85, 1048-1057.	3.4	106
27	HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. <i>PLoS Pathogens</i> , 2017, 13, e1006658.	4.7	105
28	Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. <i>PLoS Pathogens</i> , 2015, 11, e1004840.	4.7	99
29	Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. <i>Antiviral Research</i> , 2013, 99, 251-260.	4.1	98
30	Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses. <i>Journal of Virology</i> , 2018, 92, .	3.4	97
31	STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1273-1281.	3.2	93
32	A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4427-4437.	3.2	88
33	Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. <i>Antiviral Research</i> , 2006, 72, 116-124.	4.1	86
34	The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion. <i>Journal of Virology</i> , 2015, 89, 9200-9212.	3.4	84
35	Novel Imino Sugar Derivatives Demonstrate Potent Antiviral Activity against Flaviviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1501-1508.	3.2	74
36	LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2. <i>Journal of Virology</i> , 2020, 94, .	3.4	73

#	ARTICLE	IF	CITATIONS
37	Small molecule inhibitors of ER α -glucosidases are active against multiple hemorrhagic fever viruses. <i>Antiviral Research</i> , 2013, 98, 432-440.	4.1	72
38	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
39	Conditional Replication of Duck Hepatitis B Virus in Hepatoma Cells. <i>Journal of Virology</i> , 2003, 77, 1885-1893.	3.4	68
40	Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 206-216.	3.2	63
41	Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. <i>Antiviral Research</i> , 2020, 182, 104917.	4.1	62
42	Activation of Stimulator of Interferon Genes in Hepatocytes Suppresses the Replication of Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	60
43	DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. <i>PLoS Pathogens</i> , 2019, 15, e1007742.	4.7	59
44	The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy. <i>Antiviral Research</i> , 2012, 96, 405-413.	4.1	58
45	A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists. <i>Antiviral Research</i> , 2017, 147, 37-46.	4.1	55
46	Identification of Interferon-Stimulated Gene Proteins That Inhibit Human Parainfluenza Virus Type 3. <i>Journal of Virology</i> , 2016, 90, 11145-11156.	3.4	53
47	Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA. <i>Journal of Virology</i> , 2019, 93, .	3.4	53
48	Hepatitis B Virus Core Protein Dephosphorylation Occurs during Pregenomic RNA Encapsidation. <i>Journal of Virology</i> , 2018, 92, .	3.4	52
49	Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist. <i>ACS Infectious Diseases</i> , 2019, 5, 1139-1149.	3.8	50
50	Characterization of the Host Factors Required for Hepadnavirus Covalently Closed Circular (ccc) DNA Formation. <i>PLoS ONE</i> , 2012, 7, e43270.	2.5	49
51	Hepatitis B Virus Covalently Closed Circular DNA Formation in Immortalized Mouse Hepatocytes Associated with Nucleocapsid Destabilization. <i>Journal of Virology</i> , 2015, 89, 9021-9028.	3.4	49
52	Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	49
53	Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. <i>Acta Pharmaceutica Sinica B</i> , 2014, 4, 248-257.	12.0	48
54	Bat SARS-Like WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation of membrane fusion. <i>Emerging Microbes and Infections</i> , 2020, 9, 1567-1579.	6.5	48

#	ARTICLE	IF	CITATIONS
55	Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure. <i>Antiviral Research</i> , 2015, 121, 152-159.	4.1	45
56	The current status and future directions of hepatitis B antiviral drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 5-15.	5.0	44
57	Virological Basis for the Cure of Chronic Hepatitis B. <i>ACS Infectious Diseases</i> , 2019, 5, 659-674.	3.8	43
58	Does a cdc2 Kinase-Like Recognition Motif on the Core Protein of Hepadnaviruses Regulate Assembly and Disintegration of Capsids?. <i>Journal of Virology</i> , 2001, 75, 2024-2028.	3.4	39
59	Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly. <i>Journal of Virology</i> , 2017, 91, .	3.4	39
60	Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes. <i>Journal of Virology</i> , 2016, 90, 486-496.	3.4	38
61	A Novel Benzodiazepine Compound Inhibits Yellow Fever Virus Infection by Specifically Targeting NS4B Protein. <i>Journal of Virology</i> , 2016, 90, 10774-10788.	3.4	37
62	Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors. <i>ACS Infectious Diseases</i> , 2019, 5, 759-768.	3.8	34
63	Enhancing the antiviral potency of ER α -glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. <i>Antiviral Research</i> , 2018, 150, 112-122.	4.1	26
64	GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus. <i>Emerging Microbes and Infections</i> , 2019, 8, 1511-1523.	6.5	26
65	Protein phosphatase 1 catalyzes HBV core protein dephosphorylation and is co-packaged with viral pregenomic RNA into nucleocapsids. <i>PLoS Pathogens</i> , 2020, 16, e1008669.	4.7	26
66	Prospects for the Global Elimination of Hepatitis B. <i>Annual Review of Virology</i> , 2021, 8, 437-458.	6.7	26
67	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. <i>Hepatology</i> , 2020, 71, 463-476.	7.3	24
68	Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. <i>Antiviral Research</i> , 2016, 131, 40-48.	4.1	22
69	Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	21
70	Article Commentary: Viral Resistance of MOGS-CDG Patients Implies a Broad-Spectrum Strategy against Acute Virus Infections. <i>Antiviral Therapy</i> , 2015, 20, 257-259.	1.0	19
71	An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. <i>Antiviral Research</i> , 2014, 107, 56-65.	4.1	18
72	Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription. <i>Journal of Virology</i> , 2020, 94, .	3.4	18

#	ARTICLE	IF	CITATIONS
73	CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging. <i>Antiviral Research</i> , 2018, 159, 1-12.	4.1	17
74	Hepatitis B virus nucleocapsid uncoating: biological consequences and regulation by cellular nucleases. <i>Emerging Microbes and Infections</i> , 2021, 10, 852-864.	6.5	16
75	Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary?. <i>Emerging Microbes and Infections</i> , 2021, 10, 1545-1554.	6.5	12
76	Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?. <i>Hepatology</i> , 2020, 72, 1142-1144.	7.3	11
77	Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4258-4262.	2.2	10
78	Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators. <i>Antiviral Research</i> , 2021, 191, 105080.	4.1	10
79	Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis. <i>PLoS Pathogens</i> , 2021, 17, e1010057.	4.7	10
80	A yellow fever virus NS4B inhibitor not only suppresses viral replication, but also enhances the virus activation of RIG-I-like receptor-mediated innate immune response. <i>PLoS Pathogens</i> , 2022, 18, e1010271.	4.7	9
81	Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. <i>Journal of Molecular Biology</i> , 2022, 434, 167438.	4.2	7
82	Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus. <i>Medicinal Chemistry Research</i> , 2021, 30, 459-472.	2.4	6
83	Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus. <i>Antiviral Research</i> , 2020, 182, 104907.	4.1	4
84	A Putative Amphipathic Alpha Helix in Hepatitis B Virus Small Envelope Protein Plays a Critical Role in the Morphogenesis of Subviral Particles. <i>Journal of Virology</i> , 2021, 95, .	3.4	4
85	The Covalently Closed Circular Form of Hepatitis B Virus Genome: Is There Now an End in "Site"? <i>Gastroenterology</i> , 2016, 150, 34-36.	1.3	3
86	4-Oxo-octahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 58, 128518.	2.2	3
87	Alpha interferon-induced antiviral response noncytolytically reduces replication defective adenovirus DNA in MDBK cells. <i>Antiviral Research</i> , 2007, 76, 232-240.	4.1	2
88	In Vitro Anti-hepatitis B Virus Activity of 2,3-Dideoxyguanosine. <i>Virologica Sinica</i> , 2018, 33, 538-544.	3.0	2
89	HBV Drug Resistance Development, Testing, and Prevention. <i>Current Hepatitis Reports</i> , 2010, 9, 223-230.	0.3	1